Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Approval Alert | Mirdametinib in Adult/Pediatric NF1-PN
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
